Regranex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of diabetic foot ulcers, rising incidence of chronic non-healing wounds, expansion of hospital-based wound care programs, growing clinical acceptance of biologic therapies, availability of recombinant protein manufacturing capabilities.

The growth in the forecast period can be attributed to increasing diabetic population globally, rising demand for personalized wound care treatments, expansion of outpatient wound care centers, growing investment in regenerative medicine, development of next-generation biologic formulations. Major trends in the forecast period include increasing use of recombinant growth factor therapies, rising focus on advanced wound care solutions, growing adoption of targeted topical biologics, expansion of combination wound healing therapies, enhanced emphasis on chronic ulcer management.

Rising prevalence of diabetes is expected to drive the growth of the regranex market going forward. Diabetes is a collection of conditions that impact how the body regulates blood glucose levels, with the most common forms being Type 1, in which the body does not produce insulin, and Type 2, in which the body either resists insulin or does not produce sufficient amounts. The increasing prevalence of diabetes is linked to factors such as poor dietary habits, inactive lifestyles, obesity, genetic susceptibility, aging populations, and rapid urbanization. Regranex helps minimize diabetes-related complications by supporting the healing of diabetic foot ulcers, thereby reducing the risk of severe consequences such as amputations. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes rose by 22%, and for those with type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels climbed to 37.9%, the highest level ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is driving the growth of the regranex market.

The expansion of healthcare infrastructure is expected to propel the growth of the regranex market going forward. Healthcare infrastructure includes the physical and organizational frameworks, such as medical facilities, equipment, health information technology, and essential services, that support the efficient delivery of healthcare. Growth in healthcare infrastructure is driven by factors including rising healthcare needs, technological progress, public and private investments, urban expansion, pandemic readiness, healthcare policy reforms, and increasing healthcare spending. Regranex contributes to healthcare infrastructure by accelerating wound healing, lowering hospitalization rates, and improving patient outcomes, which enhances cost efficiency. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, reflecting a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the expansion of healthcare infrastructure is driving the growth of the regranex market.

In March 2025, Lynch Regenerative Medicine, LLC, a U.S.-based regenerative medicine company, acquired exclusive rights to REGRANEX gel and recombinant purified platelet-derived growth factor (PDGF) from Smith & Nephew, Inc., for an undisclosed amount. Through this acquisition, Lynch Regenerative Medicine plans to expand REGRANEX beyond its established diabetic foot ulcer indication into wider soft tissue regeneration and aesthetic wound healing applications, leveraging its expertise in pure PDGF development. Smith & Nephew, Inc. is a U.K.-based medical technology company that provides advanced wound care solutions, orthopedic products, and surgical systems.

Major companies operating in the regranex market are Smith And Nephew plc.

North America was the largest region in the regranex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the regranex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the regranex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the regranex market by increasing costs of imported recombinant proteins, bioprocessing reagents, sterile packaging materials, and specialized cold-chain logistics required for topical biologic drugs. North America and Europe are most affected due to reliance on cross-border sourcing of active pharmaceutical ingredients and formulation inputs, while Asia-Pacific faces higher production input costs for export-oriented manufacturing. These tariffs are contributing to higher treatment costs and pricing pressures in specialty wound care. However, they are also encouraging domestic biologics manufacturing, localized sourcing of formulation components, and increased investment in regional pharmaceutical supply chains.

The regranex market research report is one of a series of new reports that provides regranex market statistics, including regranex industry global market size, regional shares, competitors with a regranex market share, detailed regranex market segments, market trends and opportunities, and any further data you may need to thrive in the regranex industry. This regranex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Regranex is a topical drug that contains becaplermin, a recombinant version of platelet-derived growth factor (PDGF). It is used to support the healing of diabetic foot ulcers by enhancing tissue repair and encouraging the formation of new blood vessels.

The primary indications for Regranex include diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Diabetic foot ulcers (DFUs) are open sores on the feet that develop due to nerve damage and reduced blood flow in individuals with diabetes, which can result in infections and amputations if not properly treated. The various formulations available include topical gel, ointment, and combination therapies. The product is distributed through multiple channels, including direct sales, wholesalers, retail pharmacies, and online pharmacies, and serves a wide range of end users such as pediatric, adult, and geriatric populations.

The regranex market consists of sales of products including dermagraft, oasis wound matrix, strataGraft, apligraf, and acticoat. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.